Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Hosted on MSN1d
LEXX: IRB Approval Clears Way for GLP-1 Study #5LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
News Medical on MSN9d
Researchers create an atlas of health associations for GLP-1 receptor agonistsInsights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...
News Medical on MSN7d
Why do people with obesity, but without diabetes, start taking semaglutide?Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback